RMC-6236 / DARAXON portfolio
Daraxonrasib API
RMC-6236 active pharmaceutical ingredient for development and registration programs. U.S. FDA DMF 43871.
Product overview
Active pharmaceutical ingredient
Daraxon supplies daraxonrasib API, also known as RMC-6236, alongside two downstream SDD material formats. Discuss API specifications, quantities and the documentation required by your development program with our technical team.
PubChem · Daraxonrasib↗- Product
- Daraxonrasib API
- Development code
- RMC-6236
- Material format
- Active pharmaceutical ingredient
- Research context
- RAS(ON) multi-selective inhibitor
- U.S. FDA DMF
- 43871 · Type II
- Submission date
- 2026-03-17
- Status in the 2026 Q2 list
- A — Active
- FDA-listed holder
- SHANGHAI DA'AN XIN BIOMEDICAL CO LTD
Traceable filing record
FDA DMF 43871
Checked against the FDA 2026 Q2 DMF list. This is the only record under this product name in that quarterly list. A DMF filing is not FDA drug approval.
Technical documentation
Define the package for your program.
- Batch Certificate of Analysis and agreed product specification
- Identity and chromatographic records within the agreed documentation package
- DMF reference and Letter of Authorization requirements
Related material formats
Daraxonrasib: from API to tablet premix.
Product inquiry
Talk to the Daraxon team.
Include intended use, quantity, destination and documentation requirements.